Last reviewed · How we verify
Saline Solution, Hypertonic
Hypertonic saline solution draws fluid from intracellular and interstitial spaces into the vascular compartment through osmotic gradient, reducing intracranial pressure and cellular edema.
Hypertonic saline solution draws fluid from intracellular and interstitial spaces into the vascular compartment through osmotic gradient, reducing intracranial pressure and cellular edema. Used for Cerebral edema and elevated intracranial pressure, Traumatic brain injury, Acute stroke management.
At a glance
| Generic name | Saline Solution, Hypertonic |
|---|---|
| Also known as | intramuscular Saline injection |
| Sponsor | Medical University of Silesia |
| Drug class | Osmotic agent |
| Modality | Small molecule |
| Therapeutic area | Neurology / Critical Care |
| Phase | FDA-approved |
Mechanism of action
Hypertonic saline (typically 3%, 7%, or 23.4% NaCl) creates an osmotic gradient that pulls water from tissues into the bloodstream, thereby reducing brain swelling and intracranial pressure. It is commonly used in acute neurological emergencies to manage cerebral edema, traumatic brain injury, and increased intracranial pressure. The mechanism is purely osmotic and does not involve receptor binding or enzymatic activity.
Approved indications
- Cerebral edema and elevated intracranial pressure
- Traumatic brain injury
- Acute stroke management
- Hyponatremia correction
Common side effects
- Hyperchloremic acidosis
- Hypernatremia
- Phlebitis at infusion site
- Rebound intracranial pressure elevation
- Acute kidney injury (with prolonged use)
Key clinical trials
- Water Deprivation Protocol (NA)
- Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study (PHASE4)
- Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19) (NA)
- Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity (PHASE4)
- Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis (PHASE4)
- EuroPainClinicsStudy IX ( EPCS IX ) (NA)
- Evaluate and Understand Preferences and Representations in Families of Patients With Regard to High-throughput Sequencing Technology for Diagnostic Purposes (NA)
- Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saline Solution, Hypertonic CI brief — competitive landscape report
- Saline Solution, Hypertonic updates RSS · CI watch RSS
- Medical University of Silesia portfolio CI